Showing results (21-30 of 99) with videos related to
Sort By:
Pageof 10
Journal of Molecular Biology|April 25, 2006
Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptidesNatalia Tarnovitski, Leslie J Matthews, Jianhua Sui, et al.Protein Engineering, Design & Selection : PEDS|October 22, 2015
Reconstitution of the receptor-binding motif of the SARS coronavirusNatalia T Freund, Anna Roitburd-Berman, Jianhua Sui, et al.Cytometry. Part a : the Journal of the International Society for Analytical Cytology|November 16, 2020
High-Throughput Image Cytometry Detection Method for CAR-T Transduction, Cell Proliferation, and Cytotoxicity AssaysYufei Wang, Leo Li-Ying Chan, Marion Grimaud, et al.Immunology|November 3, 2011
Humoral immune responses in humanized BLT mice immunized with West Nile virus and HIV-1 envelope proteins are largely mediated via human CD5+ B cellsSubhabrata Biswas, Hong Chang, Phuong T N Sarkis, et al.Journal of Molecular Biology|December 9, 2003
Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivationFrancesca Gennari, Smita Mehta, Yang Wang, et al.Immuno-Oncology Insights|May 3, 2023
Preclinical models for development of immune-oncology therapiesYufei Wang, Sarah E Shelton, Gabriella Kastrunes, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2003
Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunotherapy and gene therapy strategiesDongsheng Zhang, Akikazu Murakami, R Paul Johnson, et al.Molecular Cancer|June 12, 2015
Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivoDe-Kuan Chang, Raymond J Moniz, Zhongyao Xu, et al.International Journal of Cancer|November 26, 2009
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomasChien-Tsun Kuan, Nidhi Srivastava, Roger E McLendon, et al.Molecular Cancer Therapeutics|August 25, 2006
Development of engineered antibodies specific for the Müllerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancerQing-an Yuan, Heidi H Simmons, Matthew K Robinson, et al.Pageof 10